Status:
COMPLETED
Real Life Experience Survey of Dupilumab in the Netherlands
Lead Sponsor:
Gert-Jan Braunstahl
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Severe Asthma
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: Dupilumab has proven to be effective and safe in several large randomized controlled trials. However, study populations in RCT's represent only a small proportion of severe asthma patients ...
Detailed Description
1. INTRODUCTION AND RATIONALE Background: Severe asthma is a rare condition affecting approximately 5% of all asthma patients. Patients experience daily symptoms and often have frequent exacer...
Eligibility Criteria
Inclusion
- All patients that started with dupilumab from Jan 2019 (early access program) until June 2020 are eligible for the study. They should be 18 years or older, with severe T2 high asthma and treated with at least one dose of dupilumab. All included patients should provide written informed consent.
Exclusion
- Patients with COPD (Chronic Obstructive Pulmonary Disease) or EGPA (Eosinophilic Granulomatosis with PolyAngiitis) will be excluded.
- Also, patients that had dupilumab prescribed for other reasons (nasal polyposis or atopic dermatitis) will be excluded as well.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05331755
Start Date
April 1 2021
End Date
December 31 2022
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Franciscus Gasthuis & Vlietland
Rotterdam, Netherlands, 3045PM